Published in JAMA on February 09, 2005
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace (2015) 2.67
Atrial fibrillation: established and innovative methods of evaluation and treatment. Dtsch Arztebl Int (2012) 2.43
Antithrombotic treatment in atrial fibrillation. Heart (2005) 2.00
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace (2013) 1.53
Ximelagatran--promises and concerns. JAMA (2005) 1.42
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol (2013) 1.20
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf (2011) 1.14
Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol (2012) 1.14
The new oral anticoagulants. Neth Heart J (2010) 1.06
New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke (2014) 1.00
The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Med Res Methodol (2008) 0.96
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J (2014) 0.92
The new oral anticoagulants in atrial fibrillation: an update. Neth Heart J (2013) 0.91
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol (2012) 0.88
Atrial fibrillation: challenges and opportunities. Can J Cardiol (2006) 0.87
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol (2013) 0.87
The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 0.86
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One (2014) 0.84
Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. EBioMedicine (2016) 0.83
Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol (2011) 0.83
Stroke prevention: managing modifiable risk factors. Stroke Res Treat (2012) 0.83
Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol (2008) 0.83
[Anticoagulation with atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2006) 0.82
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J (2015) 0.82
Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy? BMJ (2005) 0.80
The WATCHMAN left atrial appendage closure device for atrial fibrillation. J Vis Exp (2012) 0.80
Current strategies to minimize the bleeding risk of warfarin. J Blood Med (2013) 0.79
Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. Vasc Health Risk Manag (2013) 0.79
Costs and clinical consequences of suboptimal atrial fibrillation management. Clinicoecon Outcomes Res (2012) 0.79
Early management of atrial fibrillation: from imaging to drugs to ablation. Nat Rev Cardiol (2010) 0.78
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag (2008) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep (2016) 0.77
Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.77
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev (2013) 0.77
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiol Drug Saf (2015) 0.77
Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry? Korean Circ J (2013) 0.77
Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77
Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging (2013) 0.77
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. J Interv Card Electrophysiol (2012) 0.77
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vasc Health Risk Manag (2012) 0.76
Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. Thromb J (2007) 0.76
Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag (2006) 0.76
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised. Clin Res Cardiol (2007) 0.75
Antithrombotic therapy in cardiac embolism. Curr Cardiol Rev (2010) 0.75
Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. Can J Cardiol (2006) 0.75
Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nat Rev Cardiol (2010) 0.75
Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2015) 0.75
Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others? J Atr Fibrillation (2016) 0.75
Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. PLoS One (2016) 0.75
Left atrial appendage exclusion for atrial fibrillation. Cardiol Clin (2014) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation. Clin Res Cardiol (2015) 0.75
Also the very elderly benefit from warfarin in atrial fibrillation. Neth Heart J (2007) 0.75
Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation. ACP J Club (2005) 0.75
Stroke prevention in atrial fibrillation: latest clinical trials and guidelines. Pharmaceuticals (Basel) (2012) 0.75
LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin? Clin Med Rev Vasc Health (2013) 0.75
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract (2013) 0.75
Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Arch Toxicol (2016) 0.75
Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke. J Neurol Neurosurg Psychiatry (2007) 0.75
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol (2016) 0.75
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
Dabigatran excess: case report and review of the literature. Cardiol Ther (2013) 0.75
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. Eur J Clin Pharmacol (2007) 0.75
[Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists]. Wien Med Wochenschr (2008) 0.75
[Asymptomatic atrial fibrillation with systematic screening using tele-ECG--relevance for anticoagulation in paroxysmal atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2005) 0.75
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. J Interv Card Electrophysiol (2014) 0.75
[Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference]. Herzschrittmacherther Elektrophysiol (2007) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75
Defining the noninferiority margin and analysing noninferiority: An overview. Br J Clin Pharmacol (2017) 0.75
HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity. PLoS One (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Universal definition of myocardial infarction. Circulation (2007) 11.69
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J (2003) 6.88
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 5.44
NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation (2004) 4.45
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med (2004) 4.39
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J (2005) 2.83
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. Headache (2010) 2.72
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71